(2023)
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations.
CANCERS.
15,
22
(2023)
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
11,
4
(2023)
Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist's Perspective.
J Chest Surg.
56,
2
